Find a Physician | How to Contribute | About Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Hematology: Other hemapoietic

A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients with Advanced Hematologic Malignancies with an IDH1 and/or IDH2 Mutation

This purpose of this study is to find out how safe and tolerable the study drug AG-881 is in patients with hematological cancers which does not respond to standard treatment. Patients diagnosed with the following types of blood cancers - Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) Myeloproliferative Neoplasm (MPN) or Angioimmunoblastic T-cell Lymphoma (AITL) may qualify for the study. The main purpose of the study is to identify and test the highest dose of the study drug (AG-881) that can be given safely to patients. This drug is designed to target two proteins known as Isocitrate Dehydrogenase (IDH1 and IDH2), which have been discovered to be critical for cancer cell growth by supporting its enhanced metabolic activity. Researchers have discovered that many types of blood cancers have mutations in this protein that causes it to become overactive. The study will mainly answer the following questions: 1) the maximum dose that can be given to the patient with minimal side effects; 2) the amount of the study drug that gets into the blood stream at different time points and what it does to the body after being taken orally.

Status: PENDING
Principal Investigator: Altman

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

The purpose of this study is twofold. First,to determine if the vaccine, ASP0113, prevents or reduces cytomegalovirus (CMV)infections and complications caused by CMV. Second, to study the safety of the vaccine.

Status: Accepting New Patients
Principal Investigator: Mehta

A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

The study will try to find out if an experimental drug called pacritinib works better than best available therapies.

Status: Accepting New Patients
Principal Investigator: Stein

REDEFINE AYAO: Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology

The purpose of this study is to test an 8-week stress reduction course that is intended to reduce anxiety and improve the quality of life of adolescents and young adults diagnosed with cancer. This study will include a total of 100 participants, all of whom have been diagnosed with cancer.

Status: Accepting New Patients
Principal Investigator: Victorson

Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) with Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis

The purpose of this study is to look at the safety (side effects) and effectiveness of adding the study drug Ruxolitinib to a combination of other commonly used chemotherapy drugs (Fludarabine and Busulfan) which are taken before a stem cell transplant.

Status: Accepting New Patients
Principal Investigator: Galvin

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Dokucu

Modular phase II study to link targeted therapy to patients with pathway activated tumors:Module 6 – BGJ398 for patients with tumors with FGFR genetic alterations

Researchers want to know if BGJ398 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a FGFR regulated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.

Status: Accepting New Patients
Principal Investigator: Chae

Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 7 – Ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1

The purpose of this clinical trial is to study if ceritinib is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with an ALK or ROS1 activated pathway.

Status: Accepting New Patients
Principal Investigator: Chae

Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Cancer

The purpose of this research study is to determine a safe dose of the drug Trastuzumab and then determine how effective this treatment is.

Status: Accepting New Patients
Principal Investigator: Raizer

A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients with CD30+ and/or EBV+ Lymphomas

The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma.

Status: Accepting New Patients
Principal Investigator: Petrich

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Hitsman

Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis

There are 2 parts to this study (phase II and phase III). The part of the study in which a participant is enrolled depends on the timing of starting in the study. The purpose of the phase II part of the study is to treat the cancer that has spread to a participant's spine, and is causing pain, with image-guided radiosurgery/SBRT. The purpose of phase III is to compare the effects, good and/or bad, of image-guided radiosurgery/SBRT to standard radiation therapy to find out which treatment provides the most rapid pain relief with the least side effects.

Status: Accepting New Patients
Principal Investigator: Kalapurakal

last updated: Fri - September 04, 2015 - 05:12 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.